Mean health and social care costs over the first 2 years of life and mean cost differences between trial groups by cost category (UK £ sterling, 2007–2008 prices)
| GM-CSF (n=134) | Control (n=131) | |||||
|---|---|---|---|---|---|---|
| Cost category | Mean | (SE) | Mean | (SE) | Mean difference | (95% CI)* |
| Neonatal care | 50 464 | (2837) | 56339 | (3345) | −5875 | (−14 369 to 2620) |
| Follow-up care (to 6 months) | 5321 | (690) | 3771 | (447) | 1550 | (−43 to 3143) |
| Follow-up care (6–12 months) | 2698 | (478) | 2349 | (398) | 349 | (−863 to 1561) |
| Follow-up care (12–18 months) | 1948 | (312) | 1837 | (321) | 112 | (−772 to 995) |
| Follow-up care (18–24 months) | 1753 | (264) | 1963 | (372) | −209 | (−1104 to 686) |
| Total health and social care | 62 186 | (3517) | 66 260 | (3775) | −4073 | (−14 239 to 6093) |
↵* Bootstrap estimation using 10 000 replications, bias corrected.
GM-CSF, granulocyte-macrophage colony-stimulating factor.